In the treatment of metastatic NSCLC, there has been a downward trend in overall molecular testing and an alarming uptick in the misuse of IO, a treatment unsafe for patients with EGFR and ALK+ mutations. The IO threat campaign uses the shock element to communicate that there is obvious harm in using first-line IO in these patients.